Expert Interview
A Second View: Delving into the Phase 3 STELLAR trial data released at ACC 2023 on Merck's sotatercept for treating PAH
Ticker(s): MRK, UTHRInstitution: National Jewish Health
- Director of clinical cardiology at National Jewish Health, associate professor of clinical practice and the university of Colorado, and fellow of the American college of cardiology.
- Currently manages ~100 patients with pulmonary arterial hypertension.
- Research interests include cardiac sarcoid, public health, exercise and health outcomes, and cardiac nutrition.
How does this data reflect on the likelihood of sotatercept's approval?
Added By: max_adminHow would sotatercept impact the treatment paradigm for PAH?
Added By: max_adminOn a scale of 1-10, how would you rate your excitement for sotatercept?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
